Ferring Läkemedel AB is a pharmaceutical company based in Malmö that specializes in innovative healthcare solutions. The company is actively engaged in the research and development of specialized therapies, focusing on advancing medical science and improving patient care. Ferring has made significant strides in its financial activities, including a recent bond offering valued at CHF 330 million Swiss Francs.
In addition to its financial initiatives, Ferring has demonstrated a commitment to sustainability and corporate responsibility. The company published its 2023 Sustainability Report, which outlines its environmental efforts and initiatives. Furthermore, Ferring welcomed the publication of the journal BEYOND in Human Reproduction, indicating its involvement in advancing knowledge in the field of reproductive health. The company has also entered into a commercial gene therapy manufacturing agreement with SK pharmteco, highlighting its focus on innovative treatment options.